Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 Jul 2018

Saigi M, McLeer-Florin A, Pros E, Nadal E, Brambilla E, Sanchez-Cespedes M

Abstract excerpt

PURPOSE: Aberrant activation of MET as a result of exon 14-skipping (METex14) mutations or gene amplification is an oncogenic mechanism in non-small cell lung carcinoma (NSCLC) and a potential therapeutic target. The purpose of this study was to characterize MET alterations in a cohort of NSCLC patients treated with surgery. METHODS AND PATIENTS: 157 NSCLCs of various histopathologies, including pulmonary...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Carcinoma, Large Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Carcinoma, Squamous Cell

Share to Follow-Up Studies

Share to Gene Amplification

Share to Proto-Oncogene Proteins c-met

Share to Receptor, ErbB-2

Source

Identifiers

PMID: 29139039
DOI: 10.1007/s12094-017-1799-7

Genes

MET
ERBB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.PMID 29139039Read ↗

Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision.Semantic proximity Read ↗

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.Semantic proximity Read ↗

MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutationsSemantic proximity Read ↗

MET alterations in advanced pulmonary sarcomatoid carcinomaSemantic proximity Read ↗

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.Semantic proximity Read ↗

Novel MET exon 14 skipping analogs characterized in non-small cell lung cancer patients: A case study.Semantic proximity Read ↗

Survival outcomes and prognostic factors of lung cancer patients with the MET exon 14 skipping mutation: A single-center real-world studySemantic proximity Read ↗

Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung CancerSemantic proximity Read ↗

From knowledge to action: The journey toward targeting the MET pathway via MET exon 14 skippingSemantic proximity Read ↗

Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.Semantic proximity Read ↗

Targeting un-MET needs in advanced non-small cell lung cancer.Semantic proximity Read ↗

Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.